Exosome– tag –
-
NurExone Accelerates U.S. Market Entry with GMP Exosome Manufacturing Partnership with Made Scientific, Targeting First Batch by H1 2027
BioPharma BoardRoom USA Overview Exo-Top Inc., a U.S. subsidiary of NurExone Biologic Inc., has signed an MOU with Made Scientific, Inc. for a GMP exosome manufacturing partnership in the U.S. This strategic alliance aims to accelerate N... -
Extracellular Vesicles Emerge as Promising Biomarkers and Therapeutics for Cardiovascular Disease
Exosome-RNA.com USA Overview Researchers at Massachusetts General Hospital have highlighted the significant potential of extracellular vesicles (EVs) as both diagnostic biomarkers and therapeutic agents for cardiovascular diseases (CVD).... -
BioInformant Analyzes the Rise of Exosome Therapeutics in 2026: Potential as a Novel Modality Leveraging Intercellular Communication for New Treatments
BioInformant (Blog) USA Overview BioInformant's blog analyzes the growing role of exosome therapeutics in 2026, highlighting these extracellular vesicles as an emerging treatment modality. Exosomes, lipid bilayer vesicles 30-150 nanomete... -
FDA Warns Against Unapproved Stem Cell and Exosome Therapies, Approves Products Limited to Specific Blood Disorders
The Bridge Health & Recovery USA Overview The U.S. FDA has publicly warned against clinics marketing stem cell and exosome products with false or unsubstantiated claims. Currently, FDA-approved stem cell-based products are limited, prima... -
FDA Issues Warnings as No Approved Therapeutic Exosomes Exist in 2026 Amidst Reports of Adverse Events
OmniGenix USA Overview As of 2026, the U.S. FDA has not approved any therapeutic exosome products, issuing warnings against unauthorized sales due to reported adverse events. A 2025 review of clinical trials from 2014-2024 indicated favo... -
Exosome Therapeutics Firm Unveils Advanced Platform, Pipeline Progress Targeting Regenerative Medicine and Enhanced Drug Delivery
Company Disclosures USA Overview An exosome-based therapeutics company has detailed significant pipeline advancements and its cutting-edge technology platform at a recent investor briefing. The presentation particularly emphasized exosom... -
Unlocking Exosome Therapies for Corneal Disorders: Overcoming the Clinical Translation Challenge
Annals of Translational Medicine China Overview A recent review in *Annals of Translational Medicine* underscores the significant hurdles facing exosome-based therapies for corneal disorders, primarily in achieving manufacturing standard... -
University of Queensland Develops Scalable Engineered Extracellular Vesicles for Enhanced Targeted Delivery to Ovarian Cancer
Medical Xpress (University of Queensland) Australia Overview Researchers at the University of Queensland have developed scalable engineered extracellular vesicles (EVs) capable of targeted molecular cargo delivery to ovarian tumors. This... -
FDA Flags Unapproved Exosome Therapies, Citing Safety Concerns and International Regulatory Gaps
PLANEW Clinic South Korea Overview Exosome therapy is attracting significant attention for its regenerative potential, particularly in skin treatments, yet currently lacks U.S. FDA approval. The FDA has issued public safety warnings agai... -
Ultra-Homotypic Targeting: Lanthanide-Modified EVs Boost Cancer Detection Sensitivity by Over 25-Fold
University of Tokyo Japan Overview Researchers at the University of Tokyo, led by Professor Keisuke Goda, have unveiled a groundbreaking 'ultra-homotypic targeting' technology. By engineering extracellular vesicles (EVs) with lanthanide ...
